Family · longevity
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c; a mitochondrial-derived peptide (MDP)
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene — one of the mitochondrial-derived peptides. Preclinical work indicates it acts largely through the AMPK energy-sensing pathway: it inhibits the folate cycle and its tethered de novo purine biosynthesis, raising the endogenous AMP analog AICAR and thereby activating AMPK, which shifts cells toward glucose utilisation and improved insulin sensitivity, with skeletal muscle as a principal target. Under metabolic stress MOTS-c can also translocate to the nucleus and modulate stress-responsive and antioxidant (Nrf2-linked) gene programs. It is released into circulation and rises with exercise. Human mechanistic data remain limited.
The core MOTS-c evidence is preclinical. The founding study (Lee et al., Cell Metab 2015) showed MOTS-c improves insulin sensitivity and prevents diet-induced obesity in mice; later work described its nuclear translocation and stress-adaptive gene regulation (Kim et al., 2018) and its role as an exercise-induced regulator of physical decline and muscle homeostasis in ageing mice (Reynolds et al., Nat Commun 2021). Human data are largely observational (circulating levels vs. metabolic and exercise phenotypes); there are no adequately powered, approved-drug efficacy trials. MOTS-c is not an approved medicine.
- Preclinical research on insulin sensitivity and metabolic homeostasis
- Exercise-mimetic and skeletal-muscle signalling models
- Mitochondrial-derived peptide and AMPK pathway research
- Ageing and healthspan signalling studies in animal models
Educational overview only — no dosing instructions in the public hub.
Human safety has not been established: there are no controlled toxicity, long-term or drug-interaction data in people, and dosing, pharmacokinetics and immunogenicity of exogenous synthetic MOTS-c in humans are essentially unknown. Because it acts on AMPK and glucose handling, systemic metabolic effects are plausible but uncharacterised. As with any gray-market injectable peptide, the concrete practical risk is product quality — purity, correct sequence, endotoxin and sterility — and the absence of any medical supervision.
MOTS-c sold for research is unregulated material of unverified composition. A third-party Certificate of Analysis covering identity, purity (HPLC), quantification (to detect underfill) and mass spectrometry is the minimum verification; sterility, endotoxin and stability are typically not documented. The content here reflects preclinical findings, not a quality-assured medicine.
Research-use-only in most jurisdictions; not approved for human use by the FDA, EMA or comparable agencies, and not authorised as a dietary supplement or food ingredient. It is not a licensed medicine.
Frequently asked questions
- What is MOTS-c used for?
- Preclinical research on insulin sensitivity and metabolic homeostasis. Exercise-mimetic and skeletal-muscle signalling models. Mitochondrial-derived peptide and AMPK pathway research. Ageing and healthspan signalling studies in animal models. The core MOTS-c evidence is preclinical. The founding study (Lee et al., Cell Metab 2015) showed MOTS-c improves insulin sensitivity and prevents diet-induced obesity in mice; later work described its nuclear translocation and stress-adaptive gene regulation (Kim et al., 2018) and its role as an exercise-induced regulator of physical decline and muscle homeostasis in ageing mice (Reynolds et al., Nat Commun 2021). Human data are largely observational (circulating levels vs. metabolic and exercise phenotypes); there are no adequately powered, approved-drug efficacy trials. MOTS-c is not an approved medicine.
- Is MOTS-c legal in Europe?
- Research-use-only in most jurisdictions; not approved for human use by the FDA, EMA or comparable agencies, and not authorised as a dietary supplement or food ingredient. It is not a licensed medicine.
- What are the risks and side effects of MOTS-c?
- Human safety has not been established: there are no controlled toxicity, long-term or drug-interaction data in people, and dosing, pharmacokinetics and immunogenicity of exogenous synthetic MOTS-c in humans are essentially unknown. Because it acts on AMPK and glucose handling, systemic metabolic effects are plausible but uncharacterised. As with any gray-market injectable peptide, the concrete practical risk is product quality — purity, correct sequence, endotoxin and sterility — and the absence of any medical supervision.
- How is the quality of MOTS-c assessed?
- MOTS-c sold for research is unregulated material of unverified composition. A third-party Certificate of Analysis covering identity, purity (HPLC), quantification (to detect underfill) and mass spectrometry is the minimum verification; sterility, endotoxin and stability are typically not documented. The content here reflects preclinical findings, not a quality-assured medicine.